KR101543214B1 - Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머 - Google Patents

Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머 Download PDF

Info

Publication number
KR101543214B1
KR101543214B1 KR1020157006582A KR20157006582A KR101543214B1 KR 101543214 B1 KR101543214 B1 KR 101543214B1 KR 1020157006582 A KR1020157006582 A KR 1020157006582A KR 20157006582 A KR20157006582 A KR 20157006582A KR 101543214 B1 KR101543214 B1 KR 101543214B1
Authority
KR
South Korea
Prior art keywords
primer
sequence
seq
dna
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157006582A
Other languages
English (en)
Korean (ko)
Other versions
KR20150038659A (ko
Inventor
루스 보드
제니퍼 퍼구손
폴 프란시스 라베토
니콜라 조 텔웰
데이비드 휘트콤
Original Assignee
퀴아젠 맨체스터 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 퀴아젠 맨체스터 리미티드 filed Critical 퀴아젠 맨체스터 리미티드
Publication of KR20150038659A publication Critical patent/KR20150038659A/ko
Application granted granted Critical
Publication of KR101543214B1 publication Critical patent/KR101543214B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020157006582A 2007-09-28 2008-09-29 Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머 Expired - Fee Related KR101543214B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0719034.1 2007-09-28
GB0719034A GB2453173A (en) 2007-09-28 2007-09-28 Polynucleotide primers
PCT/GB2008/003306 WO2009040557A2 (en) 2007-09-28 2008-09-29 Polynucleotide primers for detecting pik3ca mutations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107009180A Division KR101548758B1 (ko) 2007-09-28 2008-09-29 Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머

Publications (2)

Publication Number Publication Date
KR20150038659A KR20150038659A (ko) 2015-04-08
KR101543214B1 true KR101543214B1 (ko) 2015-08-07

Family

ID=38701889

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157006582A Expired - Fee Related KR101543214B1 (ko) 2007-09-28 2008-09-29 Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머
KR1020107009180A Expired - Fee Related KR101548758B1 (ko) 2007-09-28 2008-09-29 Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머
KR1020157006583A Expired - Fee Related KR101543215B1 (ko) 2007-09-28 2008-09-29 Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머
KR1020157006584A Expired - Fee Related KR101543216B1 (ko) 2007-09-28 2008-09-29 Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020107009180A Expired - Fee Related KR101548758B1 (ko) 2007-09-28 2008-09-29 Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머
KR1020157006583A Expired - Fee Related KR101543215B1 (ko) 2007-09-28 2008-09-29 Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머
KR1020157006584A Expired - Fee Related KR101543216B1 (ko) 2007-09-28 2008-09-29 Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머

Country Status (13)

Country Link
US (4) US8901285B2 (enExample)
EP (7) EP2239341B1 (enExample)
JP (1) JP5719593B2 (enExample)
KR (4) KR101543214B1 (enExample)
CN (4) CN103834724B (enExample)
AU (1) AU2008303400B2 (enExample)
BR (1) BRPI0817444A2 (enExample)
CA (2) CA2700710C (enExample)
ES (6) ES2532225T3 (enExample)
GB (1) GB2453173A (enExample)
MX (1) MX2010003486A (enExample)
RU (1) RU2491289C2 (enExample)
WO (1) WO2009040557A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
CA3113213A1 (en) 2010-01-12 2011-07-21 Siemens Healthcare Diagnostics Inc. Oligonucleotides and methods for detecting kras mutations
JP2013081450A (ja) * 2011-09-27 2013-05-09 Arkray Inc 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット
CN102453765B (zh) * 2011-11-03 2013-07-24 厦门艾德生物医药科技有限公司 Pik3ca基因驱动突变的检测探针、引物及试剂盒
BR112014023530A2 (pt) 2012-03-29 2017-07-18 Novartis Ag diagnóstico farmacêutico
CN102816839A (zh) * 2012-07-06 2012-12-12 杭州艾迪康医学检验中心有限公司 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒
EP2711432A1 (en) * 2012-09-21 2014-03-26 Genomica S.A.U. Method for detection of BRAF and PI3K mutations
CN108130373A (zh) * 2013-03-13 2018-06-08 豪夫迈·罗氏有限公司 在人pi3kca (pik3ca)基因中检测突变的方法和组合物
CN103773837A (zh) * 2013-06-25 2014-05-07 宁波有成生物医药科技有限公司 一种pik3ca基因突变荧光定量pcr检测试剂盒及检测方法
RU2549682C1 (ru) * 2013-10-21 2015-04-27 Общество с ограниченной ответственностью "БИОЧИП-ИМБ" Способ анализа соматических мутаций в гене pi3k с использованием lna-блокирующей мультиплексной пцр и последующей гибридизацией с олигонуклеотидным биологическим микрочипом (биочипом)
WO2015161274A1 (en) * 2014-04-18 2015-10-22 Blueprint Medicines Corporation Pik3ca fusions
CN105274188A (zh) * 2014-05-29 2016-01-27 北京雅康博生物科技有限公司 Pik3ca基因突变检测试剂盒
RS59710B1 (sr) * 2014-08-07 2020-01-31 Pharmassist Ltd Metod određivanja mutacionog statusa pik3ca u uzorku
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
US10276072B2 (en) * 2014-09-03 2019-04-30 Washme Properties, Llc Illuminated sign
CN105441533B (zh) * 2014-11-29 2019-07-05 上海赛安生物医药科技有限公司 Pik3ca基因突变检测体系及其试剂盒
CN104531875A (zh) * 2014-12-30 2015-04-22 宁波有成生物医药科技有限公司 一种MyD88基因突变荧光定量PCR检测试剂盒及检测方法
WO2025110738A1 (ko) * 2023-11-24 2025-05-30 주식회사 캐니캐티케어 반려동물의 pik3ca 유전자 돌연변이성 종양 검출용 조성물 및 이를 이용한 반려동물의 pik3ca 유전자 돌연변이성 종양 진단방법
KR20250078789A (ko) 2023-11-24 2025-06-04 주식회사 캐니캐티케어 반려동물의 pik3ca 유전자 돌연변이성 종양 검출용 조성물 및 이를 이용한 반려동물의 pik3ca 유전자 돌연변이성 종양 진단방법

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
GB9208135D0 (en) * 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) * 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US20030225013A1 (en) * 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of phosphoinositide-3-kinase, regulatory subunit 4, p150 expression
US5847972A (en) 1993-09-24 1998-12-08 Eick; Stephen Gregory Method and apparatus for graphically analzying a log-file
US6043062A (en) * 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
US5948664A (en) * 1996-02-29 1999-09-07 The Regents Of The University Of California PI 3-kinase polypeptides
JP2000506396A (ja) * 1996-11-01 2000-05-30 オニックス ファーマシューティカルズ，インコーポレイティド ホスファチジルイノシトール―３′―キナーゼ関連タンパク質をコードするヌクレオチド配列及びその利用
US6277563B1 (en) * 1997-01-16 2001-08-21 The Regents Of The University Of California Genetic alterations associated with cancer
US5955277A (en) * 1997-05-05 1999-09-21 Novo Nordisk A/S Mutant cDNA encoding the p85α subunit of phosphatidylinositol 3-kinase
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US8101349B2 (en) * 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
US6537751B1 (en) 1998-04-21 2003-03-25 Genset S.A. Biallelic markers for use in constructing a high density disequilibrium map of the human genome
AU4187499A (en) * 1998-05-14 1999-11-29 Chiron Corporation Human genes and gene expression products v
GB9812768D0 (en) * 1998-06-13 1998-08-12 Zeneca Ltd Methods
US6274237B1 (en) * 1999-05-21 2001-08-14 Chisso Corporation Potentially crimpable composite fiber and a non-woven fabric using the same
AU781151B2 (en) * 1999-10-26 2005-05-12 Immusol Incorporated Ribozyme therapy for the treatment of proliferative skin and eye diseases
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AU2001294842A1 (en) * 2000-09-28 2002-04-08 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
USH2191H1 (en) * 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
CN1358850A (zh) * 2000-12-13 2002-07-17 上海博德基因开发有限公司 一种新的多肽——人磷脂酰肌醇3(PtdIns 3)－激酶17.6和编码这种多肽的多核苷酸
CA2372542A1 (en) 2001-02-20 2002-08-20 Pfizer Products Inc. Transgenic animals containing a dominant negative mutant form of the p85 subunit of pi-3 kinase
US20030162174A1 (en) * 2001-06-11 2003-08-28 Sutherland John W. Detecting nucleic acid deletion sequences
WO2003025175A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
WO2004009765A2 (en) * 2002-07-19 2004-01-29 Althea Technologies, Inc. Strategies for gene expression analysis
US7790867B2 (en) * 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
RU2240350C1 (ru) * 2003-03-11 2004-11-20 НИИ онкологии им. проф. Н.Н.Петрова Минздрава РФ Способ идентификации генных мутаций и полиморфизмов
US20070054278A1 (en) * 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
SI3296407T1 (sl) * 2004-03-02 2019-09-30 The Johns Hopkins University Mutacije gena PIK3CA pri rakih pri ljudeh
US20050287559A1 (en) * 2004-05-07 2005-12-29 Applera Corporation Genetic polymorphisms associated with vascular, methods of detection and uses thereof
US20050287570A1 (en) * 2004-05-26 2005-12-29 Wyeth Probe arrays for expression profiling of rat genes
US7981605B2 (en) * 2005-02-24 2011-07-19 Amgen Inc. Epidermal growth factor receptor mutations
WO2006094149A2 (en) * 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
KR101228854B1 (ko) * 2005-03-14 2013-02-01 코닌클리케 필립스 일렉트로닉스 엔.브이. 서비스 차별화된 무선 네트워크에서 ＱｏＳ를 측정하고감시하는 방법
GB2424886A (en) * 2005-04-04 2006-10-11 Dxs Ltd Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations
PT1948816E (pt) * 2005-10-24 2012-03-19 Univ Johns Hopkins Processos melhorados de focalização
JP4477575B2 (ja) * 2005-12-14 2010-06-09 株式会社日立製作所 大腸がんの検査に使用する遺伝子セット
AU2007225238A1 (en) 2006-03-10 2007-09-20 Wyeth Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
TW200927176A (en) * 2007-12-03 2009-07-01 Santaris Pharma As RNA antagonist compounds for the modulation of PIK3CA expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lung Cancer, Vol. 54, No. 2, pp. 209-215(2006.08.22.)

Also Published As

Publication number Publication date
KR20150038660A (ko) 2015-04-08
GB2453173A (en) 2009-04-01
US20160040255A1 (en) 2016-02-11
CN103695558A (zh) 2014-04-02
EP2505671B1 (en) 2017-02-01
WO2009040557A2 (en) 2009-04-02
RU2010116772A (ru) 2011-11-10
US10190171B2 (en) 2019-01-29
BRPI0817444A2 (pt) 2015-06-16
JP2010539920A (ja) 2010-12-24
EP2205760A2 (en) 2010-07-14
US9863003B2 (en) 2018-01-09
EP2508624B1 (en) 2015-01-14
RU2491289C2 (ru) 2013-08-27
KR101543216B1 (ko) 2015-08-07
KR20100101070A (ko) 2010-09-16
WO2009040557A3 (en) 2009-05-14
ES2622885T3 (es) 2017-07-07
AU2008303400B2 (en) 2013-09-26
EP2236627A8 (en) 2010-12-01
MX2010003486A (es) 2010-08-09
US20160032408A1 (en) 2016-02-04
EP2239341A8 (en) 2010-12-01
EP2239341A1 (en) 2010-10-13
CA2700710A1 (en) 2009-04-02
EP2505673B1 (en) 2017-02-01
US20140141425A1 (en) 2014-05-22
CA3010064A1 (en) 2009-04-02
CN103952466B (zh) 2016-07-06
CA2700710C (en) 2018-08-21
EP2239341B1 (en) 2015-01-14
EP2205760B1 (en) 2012-06-27
KR101543215B1 (ko) 2015-08-07
EP2505671A1 (en) 2012-10-03
ES2532141T3 (es) 2015-03-24
EP2505673A1 (en) 2012-10-03
US20110027779A1 (en) 2011-02-03
CN102119222A (zh) 2011-07-06
EP2236627B1 (en) 2015-01-14
ES2620289T3 (es) 2017-06-28
US10196692B2 (en) 2019-02-05
CN103695558B (zh) 2016-01-20
EP2505672B1 (en) 2015-01-14
ES2532225T3 (es) 2015-03-25
EP2508624A1 (en) 2012-10-10
CN103952466A (zh) 2014-07-30
KR101548758B1 (ko) 2015-09-01
AU2008303400A1 (en) 2009-04-02
ES2531055T3 (es) 2015-03-10
CN103834724A (zh) 2014-06-04
CN102119222B (zh) 2015-11-25
KR20150038661A (ko) 2015-04-08
ES2531994T3 (es) 2015-03-23
KR20150038659A (ko) 2015-04-08
JP5719593B2 (ja) 2015-05-20
EP2236627A1 (en) 2010-10-06
EP2505672A1 (en) 2012-10-03
CN103834724B (zh) 2016-05-25
US8901285B2 (en) 2014-12-02
GB0719034D0 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
KR101543214B1 (ko) Ｐｉｋ３ｃａ 돌연변이를 검출하기 위한 폴리뉴클레오티드 프라이머
CN102559866A (zh) Egfr基因的多态性检测用探针、扩增用引物及其应用
JP2020534820A (ja) メチル化分析のための方法
Liang et al. Quantitative analysis of activating alpha subunit of the G protein (Gsα) mutation by pyrosequencing in fibrous dysplasia and other bone lesions
JPWO2009048027A1 (ja) 免疫関連遺伝子の多型の検出用プローブおよびその用途
JP5761891B2 (ja) ポリヌクレオチドプライマー
JPWO2009011297A1 (ja) Ｊａｋ２遺伝子の変異検出用プローブおよびその用途
CN110964833B (zh) 一种一管检测血浆游离dna中kras和braf基因突变的试剂盒

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20190725

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20200804

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200804

St.27 status event code: N-4-6-H10-H13-oth-PC1903

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000